Merck stock surges 30% on strong fundamentals, regulatory catalysts, and attractive valuation. See why I rate the MRK stock a ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

Merck (MRK) stock gains as Wolfe Research upgrades the company to Outperform, while AbbVie (ABBV) falls as the firm ...

The report stated, ''Dividend investors approaching investing from a value standpoint are generally most interested in researching the strongest most profitable companies, that also happen to be ...

Merck (MRK)’s stock surged by 41% over the past six months, driven not significantly by revenue, but rather by increased profits and heightened investor confidence. Following crucial Q3 earnings ...

Forbes contributors publish independent expert analyses and insights. As a brief background, Merck develops pharmaceutical products for human health across various therapeutic areas and also creates ...

The ClearBridge Dividend Strategy underperformed its S&P 500 Index benchmark during the fourth quarter as the fund’s ...

Merck stock slumps 38% YoY; Q1 earnings could be a pivotal turning point. Analysts see 29% upside despite bearish technicals and weak recent performance. Up Next: Get 5 Dark Horse Stocks Wall Street ...

Merck (MRK) concluded the recent trading session at $110.99, signifying a +2.2% move from its prior day's close.

$MRK insiders have traded $MRK stock on the open market 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales. Here’s a ...